Abstract
Diabet. Med. 27, 1178-1187 (2010) AbstractAims Beradinelli-Seip congenital generalized lipodystrophy is a rare autosomal recessive disorder characterized by near-complete absence of adipose tissue, Herculean appearance, insulin resistance, hypoleptinaemia and diabetes mellitus. The aim of this study was to investigate the in vitro effects of pioglitazone on the expression of genes involved in adipogenesis in fibroblasts from a patient with this condition due to a seipin mutation. Methods Primary cultures of fibroblasts from the skin of the patient were obtained. Fibroblasts were treated with classic adipose differentiation medium, with and without pioglitazone. Several adipogenes were evaluated by real-time reverse transcriptase-polymerase chain reaction and western blotting. Intracellular localization of prelamin A was studied by immunofluorescence microscopy. Results The expression of the adipogenic genes PPARG, LPL, LEP and SLC2A4 was reduced in lipodystrophic fibroblasts, while treatment with pioglitazone increased the expression of these genes. Moreover, and unexpectedly, we found an accumulation of farnesylated prelamin A in lipodystrophic fibroblasts. Conclusions The process of adipocyte differentiation is compromised in patients with Beradinelli-Seip congenital lipodystrophy owing to diminished expression of the regulatory genes involved, which pioglitazone treatment partially rescues. Prelamin A accumulation establishes a link with other types of familial lipodystrophies, as familial partial lipodystrophy.
| Original language | English |
|---|---|
| Pages (from-to) | 1178-1187 |
| Number of pages | 10 |
| Journal | Diabetic Medicine |
| Volume | 27 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2010 |
Fingerprint
Keywords
- Beradinelli-Seip syndrome
- fibroblast
- gene expression
- glitazone
- seipin
ASJC Scopus subject areas
- Endocrinology
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy. / Victoria, B.; Cabezas-Agrícola, J. M.; González-Méndez, B.; Lattanzi, G.; Del Coco, R.; Loidi, L.; Barreiro, F.; Calvo, C.; Lado-Abeal, J.; Araújo-Vilar, D.
In: Diabetic Medicine, Vol. 27, No. 10, 10.2010, p. 1178-1187.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy
AU - Victoria, B.
AU - Cabezas-Agrícola, J. M.
AU - González-Méndez, B.
AU - Lattanzi, G.
AU - Del Coco, R.
AU - Loidi, L.
AU - Barreiro, F.
AU - Calvo, C.
AU - Lado-Abeal, J.
AU - Araújo-Vilar, D.
PY - 2010/10
Y1 - 2010/10
N2 - Diabet. Med. 27, 1178-1187 (2010) AbstractAims Beradinelli-Seip congenital generalized lipodystrophy is a rare autosomal recessive disorder characterized by near-complete absence of adipose tissue, Herculean appearance, insulin resistance, hypoleptinaemia and diabetes mellitus. The aim of this study was to investigate the in vitro effects of pioglitazone on the expression of genes involved in adipogenesis in fibroblasts from a patient with this condition due to a seipin mutation. Methods Primary cultures of fibroblasts from the skin of the patient were obtained. Fibroblasts were treated with classic adipose differentiation medium, with and without pioglitazone. Several adipogenes were evaluated by real-time reverse transcriptase-polymerase chain reaction and western blotting. Intracellular localization of prelamin A was studied by immunofluorescence microscopy. Results The expression of the adipogenic genes PPARG, LPL, LEP and SLC2A4 was reduced in lipodystrophic fibroblasts, while treatment with pioglitazone increased the expression of these genes. Moreover, and unexpectedly, we found an accumulation of farnesylated prelamin A in lipodystrophic fibroblasts. Conclusions The process of adipocyte differentiation is compromised in patients with Beradinelli-Seip congenital lipodystrophy owing to diminished expression of the regulatory genes involved, which pioglitazone treatment partially rescues. Prelamin A accumulation establishes a link with other types of familial lipodystrophies, as familial partial lipodystrophy.
AB - Diabet. Med. 27, 1178-1187 (2010) AbstractAims Beradinelli-Seip congenital generalized lipodystrophy is a rare autosomal recessive disorder characterized by near-complete absence of adipose tissue, Herculean appearance, insulin resistance, hypoleptinaemia and diabetes mellitus. The aim of this study was to investigate the in vitro effects of pioglitazone on the expression of genes involved in adipogenesis in fibroblasts from a patient with this condition due to a seipin mutation. Methods Primary cultures of fibroblasts from the skin of the patient were obtained. Fibroblasts were treated with classic adipose differentiation medium, with and without pioglitazone. Several adipogenes were evaluated by real-time reverse transcriptase-polymerase chain reaction and western blotting. Intracellular localization of prelamin A was studied by immunofluorescence microscopy. Results The expression of the adipogenic genes PPARG, LPL, LEP and SLC2A4 was reduced in lipodystrophic fibroblasts, while treatment with pioglitazone increased the expression of these genes. Moreover, and unexpectedly, we found an accumulation of farnesylated prelamin A in lipodystrophic fibroblasts. Conclusions The process of adipocyte differentiation is compromised in patients with Beradinelli-Seip congenital lipodystrophy owing to diminished expression of the regulatory genes involved, which pioglitazone treatment partially rescues. Prelamin A accumulation establishes a link with other types of familial lipodystrophies, as familial partial lipodystrophy.
KW - Beradinelli-Seip syndrome
KW - fibroblast
KW - gene expression
KW - glitazone
KW - seipin
UR - http://www.scopus.com/inward/record.url?scp=77956846954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956846954&partnerID=8YFLogxK
U2 - 10.1111/j.1464-5491.2010.03052.x
DO - 10.1111/j.1464-5491.2010.03052.x
M3 - Article
C2 - 20854387
AN - SCOPUS:77956846954
VL - 27
SP - 1178
EP - 1187
JO - Diabetic Medicine
JF - Diabetic Medicine
SN - 0742-3071
IS - 10
ER -